.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The Indian digital health landscape is witnessing a massive financial boost. Specifically, prominent healthcare venture capital firm HealthQuad has secured Rs 550 crore in first-close commitments for its third fund. Consequently, this milestone marks the beginning of a larger campaign to raise Rs 1,700 crore. Moreover, these funds will support early-growth companies across healthtech, medtech, biopharma, and innovative healthcare delivery models.
The new fund features a greenshoe option that could scale the total corpus to Rs 2,500 crore. Indeed, Sunil Thakur, co-founder of HealthQuad, stated that the firm expects to officially close the fund by mid-2027. Furthermore, existing global and domestic investors have driven these commitments alongside new limited partners. Interestingly, the fund has already deployed its first investment. Specifically, it backed Lifesigns, an artificial intelligence-powered remote patient monitoring system.
This fundraise follows a mutual separation of Kois and Quadria in HealthQuad in 2025. Nevertheless, the platform continues to manage its earlier portfolios. Previously, HealthQuad’s first two funds backed 18 companies, including Qure.ai, Wysa, and Redcliffe Labs. However, the firm now applies a highly rigorous vetting process. For instance, the team studies potential investees for up to four years. Specifically, they focus only on clinical-grade AI that has received solid regulatory clearance.
While Quadria Capital focuses on conventional healthcare like hospitals and pharmaceutical manufacturing, HealthQuad will target technology-led models. Consequently, this strategy ensures a clear division of investment focus. Additionally, HealthQuad operates with a completely standalone structure, team, and limited partner base. Nevertheless, it will leverage Quadria’s extensive regional network. Therefore, this dual-engine approach will help drive both traditional and digital health advancements.
Q1: What is the primary focus of HealthQuad Fund III?
HealthQuad Fund III aims to invest in early-growth companies specializing in healthtech, medtech, biopharma technology, and novel healthcare delivery models.
Q2: How does HealthQuad's investment strategy differ from Quadria Capital's approach?
While Quadria Capital targets conventional healthcare structures such as hospitals and pharmaceutical manufacturing, HealthQuad focuses exclusively on technology-enabled models and clinical-grade artificial intelligence.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
HealthQuad has secured Rs 550 crore in the first close of its third fund, targeting Rs 1,700 crore. The venture capital firm plans to back early-growth startups in healthtech, medtech, and biopharma. Its first investment went to Lifesigns, an AI-powered remote patient monitoring platform.
last month
A parliamentary panel has urged the FSSAI to finalise front-of-pack nutrition labelling regulations without further delay. The committee stressed that simple, color-coded indicators for sugar and clear warning labels are vital to combat dietary non-communicable diseases and guide informed consumer choices.
3 days back
A comprehensive analysis of the NFHS-5 data regarding postpartum anemia in India, exploring the prevalence, severity, and the socioeconomic and regional factors contributing to this public health challenge for clinicians seeking to improve maternal health outcomes.
Last week
A study in Greece reveals that 46-80% of heatwave deaths are linked to climate change. This analysis explores the implications for public health and clinical practice, particularly for elderly and vulnerable populations facing rising global temperatures in regions like India.
2 weeks back
Nearly 80% of Indians suffer from inadequate Vitamin D, causing silent bone weakening and sudden fractures. This expert guide reviews why mega-dose therapy is critical for high-risk patients, the key factors driving widespread deficiency, and the mandatory medical evaluations needed to protect skeletal health.
last month
A parliamentary standing committee has directed FSSAI to expedite front-of-pack nutrition labelling regulations. The panel highlighted that over two years of delay since the 2022 draft notification leaves consumers relying on complex numerical labels, urging simple color-coded sugar indicators and warnings.
3 days back
